Occult metastases are prognostic variables in patients with breast cancer who have negative sentinel lymph node biopsies, but the difference in five-year outcome is very small, according to a study published online Jan. 19 in the New England Journal of Medicine.
WEDNESDAY, Jan. 19 (HealthDay News) -- Occult metastases are prognostic variables in patients with breast cancer who have negative sentinel lymph node biopsies, but the difference in five-year outcome is very small, according to a study published online Jan. 19 in the New England Journal of Medicine.
Donald L. Weaver, M.D., from the University of Vermont College of Medicine in Burlington, and colleagues randomized 3,887 women with breast cancer to sentinel-lymph-node biopsy plus axillary dissection or biopsy alone. Biopsies of pathologically negative sentinel lymph nodes were further analyzed to detect all macrometastases larger than 2 mm.
The researchers identified occult metastases in 15.9 percent of the patients. Analysis indicated a significant difference between patients in whom occult metastases were detected and those in whom they were not detected with respect to overall survival, disease-free survival, and distant disease-free interval. The adjusted hazard ratios were 1.4 for death, 1.3 for any outcome event, and 1.3 for distant disease. Kaplan-Meier five-year overall survival estimates were 94.6 percent in those with occult metastases and 95.8 percent in patients without occult metastases.
"These data do not indicate a clinical benefit of additional evaluation, including immunohistochemical analysis, of initially negative sentinel nodes in patients with breast cancer," the authors write.
AbstractFull Text (subscription or payment may be required)
Related ContentPrimary breast tumor characteristics are found in distant metastasesIdentification of the Functional Role of Peroxiredoxin 6 in the Progression of Breast Cancer
Balancing VTE and bleeding risks in gynecologic cancer surgeries
December 6th 2024A comprehensive analysis shows the benefits of thromboprophylaxis often outweigh the bleeding risks during gynecologic cancer procedures, though patient-specific risk factors are crucial for decision-making.
Read More
Expert consensus sheds light on diagnosis and management of vasa previa
December 5th 2024A recent review established guidelines for prenatal diagnosis and care of vasa previa, outlining its definition, screening and diagnosis, management, and timing of delivery in asymptomatic patients.
Read More